Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032
Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the "Investor"), in a separately negotiated transaction (the "concurrent private
Rapport Therapeutics raised about $350 million through selling stock and debt. This means the company needed cash, so watch if they use it wisely on their medicine work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.